RxDoctor Payments Data

Misty Mabe, NP

Family · Norton, VANPI 1750055729

Payments from drug & device makers

$1,593in general payments, 2019–2025

Across 54 payments — averaging $29.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$565
  • Seagen Inc.$282
  • Lilly USA, LLC$203
  • Pfizer$188
  • Daiichi Sankyo Inc.$102
  • Bristol Myers Squibb$71
  • plus $181 from 7 others

What the payments were for

  • Food & beverage$75247%
  • Education$84053%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,593 in reported general payments places this provider in the 75th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$37,863
Medicare patients
167
Services billed
1,469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib14$224,956
GleevecImatinib Mesylate14$148,629
VenclextaVenetoclax16$98,618
Imatinib Mesylate18$56,965
Abiraterone Acetate17$9,671
Ondansetron Hcl104$4,454
CholestyramineCholestyramine (With Sugar)11$1,382
Letrozole60$1,308
Anastrozole103$1,153
Potassium Chloride44$636
Prochlorperazine Maleate43$629
Gabapentin36$392
Hydroxyurea20$328
Dexamethasone26$306
Methylprednisolone26$271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance$188$224,95614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,332 family providers in Virginia.

Other family in Norton

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →